Biophan to Present Technologies and Strategies at Upstate New York/Johnson & Johnson Biotech Conference.

ROCHESTER, N.Y. -- US Senator Hillary R. Clinton of New York Scheduled to Address Gathering of Industry Executives and Research Leaders

Biophan Technologies, Inc. (OTCBB: BIPH; Frankfurt/FSE: BTN), a developer of next-generation medical technology, has announced that CEO Michael Weiner will present a comprehensive outline of the Company's growth strategy in several multi-billion dollar segments of the healthcare industry at the Upstate New York/Johnson & Johnson Biotech Conference, scheduled to be held October 10, 2005 at the University of Rochester Medical Center, in Rochester, NY. The conference is being hosted by healthcare product manufacturer Johnson & Johnson (NYSE: JNJ) and New Jobs New York, to foster relationships between Johnson & Johnson and local biotech companies.

US Senator Hillary R. Clinton of New York is scheduled to make an address at the conference. Also attending will be Roy Davis, company group chairman, Johnson & Johnson and Roger C. Altman, chairman of New Jobs New York. Executives of biotechnology companies, as well as research leaders from five institutions throughout Western and Central New York are also expected to attend.

Mr. Weiner's presentation will include discussions of the Company's technologies to enhance products for the medical device industry. He also will discuss the Company's business model. Subjects Mr. Weiner expects to cover include:

--Biophan's suite of proprietary solutions to enable Magnetic Resonance Imaging (MRI) safety and image compatibility for the $12 billion worth of medical devices shipped annually with MRI limitations, including pacemakers, stents and surgical tools;

--Nanotechnology-based innovations in the growing $40 billion* advanced drug-delivery and drug-elution marketplace;

--A unique ventricular assist device (VAD) called the MYO-VAD, that is designed to maintain blood circulation in patients suffering from heart failure. By not coming into contact with circulating blood the MYO-VAD promises to provide substantial advantages over today's devices by minimizing or eliminating the primary sources of VAD complications such as bleeding, stroke and infection.

--An MRI-safe, ultra-precise, non-magnetic motor, that is made of ceramic materials and can be used in implantable drug-pumps and other applications.

--An implantable and long-lasting biothermal power source that is powered by human body heat, to power medical devices such as neurostimulators and pacemakers. Biophan is working with NASA to develop this power source with an extended service life, enabled by Biophan's patented technology.

--Industry recognition of the Company's technology expertise and intellectual property portfolio, including Frost & Sullivan's Excellence in Medical Imaging Technology of the Year Award in 2004.

*Frost & Sullivan

"Biophan is delighted to be invited to participate in the Upstate New York Biotech Day hosted by Johnson & Johnson and New Jobs New York," said Mr. Weiner. "As a technology innovator, Biophan recognizes and supports the need for strong relationships among all of those conducting important primary research in industry and academia, as well as among all the companies that are working to bring new discoveries to the marketplace. Technology innovation is helped enormously by programs such as this."

The PowerPoint segment of Mr. Weiner's presentation at the conference can be viewed at http://www.biophan.com/presentations.php.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops technologies that enable implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and devices such as stents to be safely and effectively imaged under MRI. Biophan is developing these same technologies to provide new MRI contrast agents. Other applications include drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 156 U.S. patents, licenses, or applications. This total includes 42 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 106 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development and licensing agreements with Boston Scientific and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. Biophan is also listed on the Frankfurt Stock Exchange under the ticker symbol BTN. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.